IP Library Granted Patent US 8,017,727
Granted Patent B2
US 8,017,727 · App. 12/645,922 · Granted Sep 13, 2011

Conjugates of membrane translocating agents and pharmaceutically active agents

Assignee: Merrion Research III Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,017,727
App. No.
12/645,922
Granted
Sep 13, 2011
Kind
B2
Abstract

Membrane translocation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.

Claims (12)

1. A composition comprising a translocating peptide, wherein said translocating peptide is a transport peptide or an extended peptide comprising said transport peptide, wherein said transport peptide is a retroinverted peptide and wherein the retroinverted peptide comprises a d-form amino acid sequence selected from the group consisting of a peptide of SEQ ID NOS:85 and 95-103 and the retroinverted sequence of SEQ ID NO:120.

2. The composition of claim 1 , wherein the transport peptide is partially or completely cyclic.

3. The composition of claim 1 , wherein the transport peptide is completely cyclic.

4. The composition of claim 1 , wherein the carboxyl end group of the translocating peptide has been modified to create an amide group.

5. A chimeric polypeptide comprising (A) a translocating peptide selected from the group consisting of a transport peptide, an extended peptide comprising said transport peptide, and a transport-active fragment of at least 4 contiguous amino acids of said transport peptide, wherein said transport peptide is a retroinverted peptide and wherein the retroinverted peptide comprises a d-form amino acid sequence selected from the group consisting of a peptide of SEQ ID NOS:85 and 95-103 and the retroinverted sequence of SEQ ID NO:120, (B) a translocatable peptide, and (C) an amino acid linker sequence that directly links the translocating peptide to the translocatable peptide, wherein said translocatable peptide is between 3 and 200 amino acids, and wherein said amino acid linker sequence is between 1 and 20 amino acids.

6. The chimeric peptide of claim 5 wherein said translocatable peptide is between 3 and 30 amino acids.

7. The chimeric peptide of claim 5 wherein the translocatable peptide is an opioid peptide.

8. The chimeric peptide of claim 5 wherein said linker sequence is not more than 7 amino acids.

9. A composition comprising a translocating peptide, said translocating peptide selected from the group consisting of a transport peptide, an extended peptide comprising said transport peptide, and a transport-active fragment of at least 4 contiguous amino acids of said transport peptide, wherein said transport peptide a retroinverted peptide and wherein the retroinverted peptide comprises a d-form amino acid sequence selected from the group consisting of a peptide of SEQ ID NOS:85 and 95-103 and the retroinverted sequence of SEQ ID NO:120, and wherein said transport peptide is partially or completely cyclic.

10. A composition comprising a translocating peptide, said translocating peptide selected from the group consisting of a transport peptide, an extended peptide comprising said transport peptide, and a transport-active fragment of at least 4 contiguous amino acids of said transport peptide, wherein said transport peptide a retroinverted peptide and wherein the retroinverted peptide comprises a d-form amino acid sequence selected from the group consisting of a peptide of SEQ ID NOS:85 and 95-103 and the retroinverted sequence of SEQ ID NO:120, and wherein said transport-active fragment is partially or completely cyclic.

11. The composition of claim 9 , wherein said transport peptide is completely cyclic.

12. The composition of claim 10 , wherein said transport-active fragment is completely cyclic.

Continuity (7)
Continuation 11303372 · Dec 16, 2005
Continuation 10955656 · Sep 30, 2004
Continuation 10126845 · Apr 19, 2002
Continuation In Part 09671089 · Sep 27, 2000
Provisional Application 60156246 · Sep 27, 1999
Provisional Application 60287786 · Apr 30, 2001
Related Publication 20100168381A1 · Jul 1, 2010